• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Battling Inequities in Access to PrEP

Video

Carl Schmid describes the steps that can be taken to reduce inequities in PrEP uptake, focusing on community and provider education.

Carl Schmid: There’s so much that can be done to address the inequities in PrEP [pre-exposure prophylaxis] uptake. We need a concerted, federally funded program focusing on 2 things: the community, to make sure that those who should be taking PrEP are aware of it, and provider education. We need providers, particularly in the South, who treat the people who are in most need of PrEP to center on them and talk with their patients about sex, the stigma, and why they should be talking about PrEP. But also the opportunities for PrEP. The opportunity for PrEP starts with a discussion about HIV. It starts with an HIV test. We need doctors to be talking about those things. It’s not just PrEP; it’s preventing and treating HIV. If you have a patient who’s living with HIV, you have to begin by talking with them about it and then get them to take a test, which they have to agree to.

We’re advocating a nationwide PrEP grant program that would build up on the existing systems that the CDC [Centers for Disease Control and Prevention] has right now. They have grants that go out to the states to community-based organizations. We need to build on that. They can’t spend money on PrEP drugs right now. They’re just starting to spend money on PrEP laboratory services. We need to ramp up the education components. We need to ramp up the availability of PrEP services and pay for PrEP itself.

Then there’s another component with the community health centers. There are 1400 community health centers around the country that serve predominately lower income people. We’ve just started a PrEP program there, but it’s only reaching about 150 clinics. We need to ramp those up and we need to ramp it up around the country. There are some bills in Congress right now that have been introduced to establish these PrEP grant programs. We’re also anxiously awaiting what’s in the President’s budget. I think that he will focus on PrEP as well. We need to ramp up community outreach, provider outreach, and provide PrEP, particularly for those who are underinsured or without insurance.

This transcript has been edited for clarity.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
© 2024 MJH Life Sciences

All rights reserved.